Hwail Pharmaceutical Co.Ltd (061250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.82 Billion ≈ $4.62 Million USD) by net assets (₩207.86 Billion ≈ $140.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Hwail Pharmaceutical Co.Ltd for the company's overall valuation and market capitalisation.
Hwail Pharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Hwail Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hwail Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hwail Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency. Explore 061250 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhangjiagang Zhonghuan Hailu High-End Equipment Co. Ltd.
SHE:301040
|
N/A |
|
Akastor ASA
OL:AKAST
|
0.003x |
|
American Exceptionalism Acquisition Corp. A
NYSE:AEXA
|
0.000x |
|
Wuhan Xingtu Xinke Electronics Co Ltd
SHG:688081
|
-0.047x |
|
Universal Store Holdings Ltd
AU:UNI
|
0.201x |
|
Lanpec Technologies Ltd
SHG:601798
|
0.028x |
|
Lontrue Co Ltd
SHE:300175
|
-0.111x |
|
Jiangsu Jiuwu Hi-Tech Co Ltd
SHE:300631
|
0.064x |
Annual Cash Flow Conversion Efficiency for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. View Hwail Pharmaceutical Co.Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩203.42 Billion ≈ $137.85 Million |
₩11.63 Billion ≈ $7.88 Million |
0.057x | +42.04% |
| 2023-12-31 | ₩174.45 Billion ≈ $118.22 Million |
₩7.02 Billion ≈ $4.76 Million |
0.040x | +3126.94% |
| 2022-12-31 | ₩175.57 Billion ≈ $118.98 Million |
₩-233.56 Million ≈ $-158.28K |
-0.001x | -101.20% |
| 2021-12-31 | ₩181.66 Billion ≈ $123.11 Million |
₩20.09 Billion ≈ $13.61 Million |
0.111x | +8700.50% |
| 2020-12-31 | ₩156.86 Billion ≈ $106.30 Million |
₩-201.69 Million ≈ $-136.68K |
-0.001x | -104.16% |
| 2019-12-31 | ₩119.43 Billion ≈ $80.94 Million |
₩3.69 Billion ≈ $2.50 Million |
0.031x | -56.33% |
| 2018-12-31 | ₩101.25 Billion ≈ $68.61 Million |
₩7.17 Billion ≈ $4.86 Million |
0.071x | -16.62% |
| 2017-12-31 | ₩98.18 Billion ≈ $66.53 Million |
₩8.34 Billion ≈ $5.65 Million |
0.085x | -11.50% |
| 2016-12-31 | ₩99.86 Billion ≈ $67.67 Million |
₩9.58 Billion ≈ $6.49 Million |
0.096x | +237.50% |
| 2015-12-31 | ₩98.94 Billion ≈ $67.05 Million |
₩-6.90 Billion ≈ $-4.68 Million |
-0.070x | -123.28% |
| 2014-12-31 | ₩89.07 Billion ≈ $60.36 Million |
₩-2.78 Billion ≈ $-1.89 Million |
-0.031x | -138.69% |
| 2013-12-31 | ₩86.31 Billion ≈ $58.49 Million |
₩6.97 Billion ≈ $4.72 Million |
0.081x | +561.06% |
| 2012-12-31 | ₩82.22 Billion ≈ $55.72 Million |
₩1.00 Billion ≈ $680.89K |
0.012x | -89.19% |
| 2011-12-31 | ₩69.49 Billion ≈ $47.09 Million |
₩7.86 Billion ≈ $5.32 Million |
0.113x | -- |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.